Combination 408

A pharmaceutical product, wherein the product comprises:

• N-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a pharmaceutically acceptable salt thereof, wherein:
• the counter-ion of the salt is chloride, bromide, sulfate, methanesulfonate, benzenesulfonate (besylate), toluenesulfonate (tosylate), napthalenebissulfonate (napadisylate), phosphate, acetate, citrate, lactate, tartrate, mesylate, maleate, fumarate, or succinate;
• and
• (R)-1-[2-(4-Fluoro-phenyl)-ethyl]-3-((S)-2-phenyl-2-piperidin-1-yl-propionyloxy)-1-azonia-bicyclo[2.2.2]octane.

A method of treating a respiratory disease, wherein:

• the method comprises simultaneously, sequentially, or separately administering to a patient in need thereof:
• (a) a therapeutically effective dose of N-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a salt thereof;
• and
• (b) a therapeutically effective dose of a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist;
• an antioxidant;
• a CCR1 antagonist;
• a chemokine antagonist (not CCR1);
• a corticosteroid;
• a CRTh2 antagonist;
• a DP1 antagonist;
• an Histone Deacetylase Inducer;
• an IKK2 inhibitor;
• a COX inhibitor;
• a lipoxygenase inhibitor;
• a leukotriene receptor antagonist;
• an MPO inhibitor;
• a muscarinic antagonist;
• a p38 inhibitor;
• a PDE inhibitor;
• a PPARγ agonist;
• a protease inhibitor;
• a Statin;
• a thromboxane antagonist;
• a vasodilator;
• or an ENAC blocker (Epithelial Sodium-channel blocker);
• the muscarinic antagonist is not:
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyrazin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridazin-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-[1-(3-Fluoro-phenyl)-cycloheptanecarbonyloxy]-1-(pyrazin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-[1-(3-Fluoro-phenyl)-cycloheptanecarbonyloxy]-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-1-[(5-Fluoro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• or
• (R)-1-[(2-Methyl-pyridin-4-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane X;
• and
• X is a pharmaceutically acceptable anion of a mono or polyvalent acid.

A pharmaceutical composition, wherein:

• the composition comprises, in admixture:
• N-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a salt thereof, and
• a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist;
• an antioxidant;
• a CCR1 antagonist;
• a chemokine antagonist (not CCR1);
• a corticosteroid;
• a CRTh2 antagonist;
• a DP1 antagonist;
• an Histone Deacetylase Inducer;
• an IKK2 inhibitor;
• a COX inhibitor;
• a lipoxygenase inhibitor;
• a leukotriene receptor antagonist;
• an MPO inhibitor;
• a muscarinic antagonist;
• a p38 inhibitor;
• a PDE inhibitor;
• a PPARγ agonist;
• a protease inhibitor;
• a Statin;
• a thromboxane antagonist;
• a vasodilator;
• or an ENAC blocker (Epithelial Sodium-channel blocker);
• the muscarinic antagonist is not:
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyrazin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridazin-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-[1-(3-Fluoro-phenyl)-cycloheptanecarbonyloxy]-1-(pyrazin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-[1-(3-Fluoro-phenyl)-cycloheptanecarbonyloxy]-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-2-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-1-[(5-Fluoro-pyridin-2-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane X;
• (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane X;
• or
• (R)-1-[(2-Methyl-pyridin-4-ylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane X;
• and
• X is a pharmaceutically acceptable anion of a mono or polyvalent acid.